[
  {
    "ts": null,
    "headline": "ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape | DelveInsight",
    "summary": "The annual conference presented over 100 scientific sessions featuring innovations from leading pharmaceutical companies, including Novo Nordisk, Eli Lilly and Company, Viking Therapeutics, Ascletis Pharma, Skye Bioscience, Palatin Technologies, Inc., Neurogastrx, Inc., OrsoBio, Metsera, and others, revealing not only significant advances in drug efficacy but also reshaping the multibillion-dollar obesity therapeutics market. These presentations collectively demonstrate that obesity management h",
    "url": "https://finnhub.io/api/news?id=1a79aefb2b82934493f34c7df978affd65f5a85cc8593c483d454789834423d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763073060,
      "headline": "ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape | DelveInsight",
      "id": 137475599,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The annual conference presented over 100 scientific sessions featuring innovations from leading pharmaceutical companies, including Novo Nordisk, Eli Lilly and Company, Viking Therapeutics, Ascletis Pharma, Skye Bioscience, Palatin Technologies, Inc., Neurogastrx, Inc., OrsoBio, Metsera, and others, revealing not only significant advances in drug efficacy but also reshaping the multibillion-dollar obesity therapeutics market. These presentations collectively demonstrate that obesity management h",
      "url": "https://finnhub.io/api/news?id=1a79aefb2b82934493f34c7df978affd65f5a85cc8593c483d454789834423d2"
    }
  },
  {
    "ts": null,
    "headline": "Can Equities Stabilize after the Government Reopens?",
    "summary": "As traders position for year-end, the government shutdown is over, major market indices are filling gaps, and seasonal momentum looms.",
    "url": "https://finnhub.io/api/news?id=1f74dbfaea93932409cf1179b01392a59cd4924be791d02d6c4687c69d5ab397",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763056020,
      "headline": "Can Equities Stabilize after the Government Reopens?",
      "id": 137473174,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As traders position for year-end, the government shutdown is over, major market indices are filling gaps, and seasonal momentum looms.",
      "url": "https://finnhub.io/api/news?id=1f74dbfaea93932409cf1179b01392a59cd4924be791d02d6c4687c69d5ab397"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Discusses Key Point For Eli Lilly (LLY)’s Drugs",
    "summary": "We recently published Jim Cramer Discussed These 25 Stocks In An Important Show About AI Spending. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) is the pharmaceutical giant best known for its weight loss drugs. Cramer regularly discusses the firm in his morning appearances […]",
    "url": "https://finnhub.io/api/news?id=77c271fa7352ead17a154c0921408159a3c82ef9caa52f04e73e8421f40752d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763051821,
      "headline": "Jim Cramer Discusses Key Point For Eli Lilly (LLY)’s Drugs",
      "id": 137470094,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published Jim Cramer Discussed These 25 Stocks In An Important Show About AI Spending. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) is the pharmaceutical giant best known for its weight loss drugs. Cramer regularly discusses the firm in his morning appearances […]",
      "url": "https://finnhub.io/api/news?id=77c271fa7352ead17a154c0921408159a3c82ef9caa52f04e73e8421f40752d5"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Praises Johnson & Johnson (JNJ)’s Drugs",
    "summary": "We recently published Jim Cramer Discussed These 25 Stocks In An Important Show About AI Spending. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) is one of the biggest healthcare and pharmaceutical companies in the world. The firm recently spun off its orthopedic business, and Cramer […]",
    "url": "https://finnhub.io/api/news?id=fc4c22310a57aad4fceefa790e332f5c66a104d62907919d0b0366cbd772c3c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763051771,
      "headline": "Jim Cramer Praises Johnson & Johnson (JNJ)’s Drugs",
      "id": 137469139,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published Jim Cramer Discussed These 25 Stocks In An Important Show About AI Spending. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) is one of the biggest healthcare and pharmaceutical companies in the world. The firm recently spun off its orthopedic business, and Cramer […]",
      "url": "https://finnhub.io/api/news?id=fc4c22310a57aad4fceefa790e332f5c66a104d62907919d0b0366cbd772c3c9"
    }
  },
  {
    "ts": null,
    "headline": "Hypoglycemia Market Report 2025: Pipeline Holds 16 Molecules, with No Assets in the Pre-registration Stage, Three Assets in Phase III Development, and Another Four in Phase II",
    "summary": "Key market opportunities in hypoglycemia therapeutics include leveraging the high incidence in India for market expansion and innovation, targeting the three Phase III pipeline assets for accelerated development, and capitalizing on recent strategic alliances and M&A activities to enhance competitive positioning.Dublin, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The \"Hypoglycemia: Market View\" report has been added to ResearchAndMarkets.com's offering.This reports provides a data-driven overview of the c",
    "url": "https://finnhub.io/api/news?id=9910ec4c2c9c09b136405d46cfe1e0615e080f84651b1b209878d6ee7059fd86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763049240,
      "headline": "Hypoglycemia Market Report 2025: Pipeline Holds 16 Molecules, with No Assets in the Pre-registration Stage, Three Assets in Phase III Development, and Another Four in Phase II",
      "id": 137469127,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Key market opportunities in hypoglycemia therapeutics include leveraging the high incidence in India for market expansion and innovation, targeting the three Phase III pipeline assets for accelerated development, and capitalizing on recent strategic alliances and M&A activities to enhance competitive positioning.Dublin, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The \"Hypoglycemia: Market View\" report has been added to ResearchAndMarkets.com's offering.This reports provides a data-driven overview of the c",
      "url": "https://finnhub.io/api/news?id=9910ec4c2c9c09b136405d46cfe1e0615e080f84651b1b209878d6ee7059fd86"
    }
  },
  {
    "ts": null,
    "headline": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
    "summary": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=5aafec13e5283a7c16cdd2ef7a281b860ab6773670749212b5df63a2284578b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763045138,
      "headline": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
      "id": 137468541,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=5aafec13e5283a7c16cdd2ef7a281b860ab6773670749212b5df63a2284578b0"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Long-Term Brand Dominance At A Bargain",
    "summary": "Novo Nordisk remains a dominant business with a strong pipeline, and current multiples are low enough to justify a buy. Read my latest analysis of NVO stock.",
    "url": "https://finnhub.io/api/news?id=4f80de74de5c4ba5c96690e94dd78711ad93baf95a8e4725a2d14a251bc4e722",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763044360,
      "headline": "Novo Nordisk: Long-Term Brand Dominance At A Bargain",
      "id": 137471748,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305436/image_2158305436.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk remains a dominant business with a strong pipeline, and current multiples are low enough to justify a buy. Read my latest analysis of NVO stock.",
      "url": "https://finnhub.io/api/news?id=4f80de74de5c4ba5c96690e94dd78711ad93baf95a8e4725a2d14a251bc4e722"
    }
  },
  {
    "ts": null,
    "headline": "Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month",
    "summary": "As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.",
    "url": "https://finnhub.io/api/news?id=0ebd026705a2df955b5b59eeac8517a760fd1aabc7ae06352a82323174b8fa94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763039220,
      "headline": "Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month",
      "id": 137468248,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.",
      "url": "https://finnhub.io/api/news?id=0ebd026705a2df955b5b59eeac8517a760fd1aabc7ae06352a82323174b8fa94"
    }
  },
  {
    "ts": null,
    "headline": "MeiraGTx Reports Third Quarter 2025 Financial and Operational Results",
    "summary": "Entered into broad strategic collaboration with Eli Lilly and Company (“Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company’s AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 (LCA4) Released material under the Company’s Specials license for a second rare pediatric ophthalmology condition caused by mutations in BBS10, with the prescribing physician treating the first patient during the quarte",
    "url": "https://finnhub.io/api/news?id=88e9eb635d5c7642f29a0cad02fb10ed832ceb4156072d64b76fc2e1e0f1cc66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763038800,
      "headline": "MeiraGTx Reports Third Quarter 2025 Financial and Operational Results",
      "id": 137468249,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Entered into broad strategic collaboration with Eli Lilly and Company (“Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company’s AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 (LCA4) Released material under the Company’s Specials license for a second rare pediatric ophthalmology condition caused by mutations in BBS10, with the prescribing physician treating the first patient during the quarte",
      "url": "https://finnhub.io/api/news?id=88e9eb635d5c7642f29a0cad02fb10ed832ceb4156072d64b76fc2e1e0f1cc66"
    }
  },
  {
    "ts": null,
    "headline": "LLY: Eli Lilly Stock Climbs After Exiting CVS Drug Plan",
    "summary": "Eli Lilly Dumps CVS Health Plan After Coverage Rift on Weight-Loss Drugs",
    "url": "https://finnhub.io/api/news?id=fe9e0d3eaa18676de248cb03611f920abf1193b7f3f4a3153e425820674b3e70",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763036797,
      "headline": "LLY: Eli Lilly Stock Climbs After Exiting CVS Drug Plan",
      "id": 137468250,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly Dumps CVS Health Plan After Coverage Rift on Weight-Loss Drugs",
      "url": "https://finnhub.io/api/news?id=fe9e0d3eaa18676de248cb03611f920abf1193b7f3f4a3153e425820674b3e70"
    }
  },
  {
    "ts": null,
    "headline": "Mangoceuticals Partners with Eli Lilly and Novo Nordisk to Deliver Affordable Access to Zepbound and Wegovy for Obesity Management",
    "summary": "Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (\"Mangoceuticals\" or the \"Company\"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, is excited to announce that it has launched MangoRx Direct and PeachesRx Direct, two integrated programs that provide direct access to authentic Zepbound® (t",
    "url": "https://finnhub.io/api/news?id=10a64b15da25fdb7145703350ac2f5ae7071003b41e4c858755099535365b638",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763035200,
      "headline": "Mangoceuticals Partners with Eli Lilly and Novo Nordisk to Deliver Affordable Access to Zepbound and Wegovy for Obesity Management",
      "id": 137468251,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (\"Mangoceuticals\" or the \"Company\"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, is excited to announce that it has launched MangoRx Direct and PeachesRx Direct, two integrated programs that provide direct access to authentic Zepbound® (t",
      "url": "https://finnhub.io/api/news?id=10a64b15da25fdb7145703350ac2f5ae7071003b41e4c858755099535365b638"
    }
  },
  {
    "ts": null,
    "headline": "Here Are the Top Growth Healthcare Stocks Every New Investor Should Know",
    "summary": "These top growth stocks have plenty of room left to run.",
    "url": "https://finnhub.io/api/news?id=ea8176196533f6ec04b0b7df1ff8d7a877b93475688f7f72bc7061c25a773440",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763028900,
      "headline": "Here Are the Top Growth Healthcare Stocks Every New Investor Should Know",
      "id": 137466724,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These top growth stocks have plenty of room left to run.",
      "url": "https://finnhub.io/api/news?id=ea8176196533f6ec04b0b7df1ff8d7a877b93475688f7f72bc7061c25a773440"
    }
  },
  {
    "ts": null,
    "headline": "2 Quality Healthcare Stocks That Could Build a Strong Foundation for Beginner Investors",
    "summary": "Healthcare stocks have plenty to offer new investors.",
    "url": "https://finnhub.io/api/news?id=c19b608c9090d27d362e960662d2e4f23bf985ec78ce2eb389b424089562511f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763026800,
      "headline": "2 Quality Healthcare Stocks That Could Build a Strong Foundation for Beginner Investors",
      "id": 137466725,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Healthcare stocks have plenty to offer new investors.",
      "url": "https://finnhub.io/api/news?id=c19b608c9090d27d362e960662d2e4f23bf985ec78ce2eb389b424089562511f"
    }
  },
  {
    "ts": null,
    "headline": "1 Incredible Reason to Buy LLY's Stock in November",
    "summary": "Eli Lilly struck a deal with President Donald Trump last week that could send the stock much higher.",
    "url": "https://finnhub.io/api/news?id=0dda0ab3177e6218d231d3079e9a5283fcc1bc14b836d4ee830dc22d91682775",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763025900,
      "headline": "1 Incredible Reason to Buy LLY's Stock in November",
      "id": 137466726,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly struck a deal with President Donald Trump last week that could send the stock much higher.",
      "url": "https://finnhub.io/api/news?id=0dda0ab3177e6218d231d3079e9a5283fcc1bc14b836d4ee830dc22d91682775"
    }
  },
  {
    "ts": null,
    "headline": "1 Unpopular Stock That Deserves a Second Chance and 2 We Question",
    "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
    "url": "https://finnhub.io/api/news?id=c2a60999ea949c5bce661ffe4c8ea902d9db86651c9d73ce966446a3b08e67d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763008560,
      "headline": "1 Unpopular Stock That Deserves a Second Chance and 2 We Question",
      "id": 137469129,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
      "url": "https://finnhub.io/api/news?id=c2a60999ea949c5bce661ffe4c8ea902d9db86651c9d73ce966446a3b08e67d3"
    }
  },
  {
    "ts": null,
    "headline": "CNBC Daily Open: There's the AI market, and then there's 'everything else'",
    "summary": "What investors would really like is if fork in the markets merges into one. That tends to be the safer path to take.",
    "url": "https://finnhub.io/api/news?id=de8bc8a94593d4fe2cc6c508d6c58289ed7a6a68ed4c7c49b7b4731f41eec836",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763001001,
      "headline": "CNBC Daily Open: There's the AI market, and then there's 'everything else' ",
      "id": 137469677,
      "image": "https://image.cnbcfm.com/api/v1/image/108225074-1762983658195-gettyimages-2246411412-anotherday145729043_yoydhjpi.jpeg?v=1762983736&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "What investors would really like is if fork in the markets merges into one. That tends to be the safer path to take.",
      "url": "https://finnhub.io/api/news?id=de8bc8a94593d4fe2cc6c508d6c58289ed7a6a68ed4c7c49b7b4731f41eec836"
    }
  },
  {
    "ts": null,
    "headline": "Citigroup Maintains Eli Lilly and (LLY) Buy Recommendation",
    "summary": "Citigroup Maintains Eli Lilly and (LLY) Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=9d55d5066b3ec4221ef1cf92fff2b3046eb9018461dd661e4cce55a4e67b6d40",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762992175,
      "headline": "Citigroup Maintains Eli Lilly and (LLY) Buy Recommendation",
      "id": 137463708,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=9d55d5066b3ec4221ef1cf92fff2b3046eb9018461dd661e4cce55a4e67b6d40"
    }
  }
]